Get the Stockscreener App
16.17
11.59%
1.68
After Hours:
16.17
Cadrenal Therapeutics Inc stock is traded at $16.17, with a volume of 201.03K.
It is up +11.59% in the last 24 hours and up +11.52% over the past month.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
See More
Previous Close:
$14.49
Open:
$15.89
24h Volume:
201.03K
Relative Volume:
2.93
Market Cap:
$26.82M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-23.06
EPS:
-0.7012
Net Cash Flow:
$-3.95M
1W Performance:
+44.38%
1M Performance:
+11.52%
6M Performance:
+134.86%
1Y Performance:
+107.31%
1-Day Range:
$15.33
$18.00
1-Week Range:
$10.65
$18.00
52-Week Range:
$5.40
$32.55
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
16.17 | 26.82M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - The Eastern Progress Online
CVKDCadrenal Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cadrenal Therapeutics to Showcase Novel Anticoagulant Tecarfarin at J.P. Morgan Healthcare Conference - StockTitan
(CVKD) Trading Report - Stock Traders Daily
What is Zacks Small Cap’s Estimate for CVKD FY2024 Earnings? - Defense World
CVKD: Recent Financings Raise $9.8 Million… - MSN
Kairos Pharma approved to dual list on Upstream - MSN
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - StockTitan
(CVKD) Technical Data - Stock Traders Daily
ARMISTICE CAPITAL, LLC Acquires New Stake in Cadrenal Therapeuti - GuruFocus.com
Cadrenal's Tecarfarin Shows Promise for LVAD Patients in Key Medical Congress Data | CVKD Stock News - StockTitan
Cadrenal shares gain; analyst highlights Buy rating and key LVAD trial advancements - Investing.com Canada
Cadrenal Therapeutics Provides Third-Quarter Corporate Update - Defense World
(CVKD) Long Term Investment Analysis - Stock Traders Daily
Cadrenal Therapeutics Advances Tecarfarin Development - TipRanks
Cadrenal Therapeutics Raises $9.8M, Advances Unique Anticoagulant Drug Development | CVKD Stock News - StockTitan
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds - StockTitan
Here's Why We're Watching Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation - Simply Wall St
We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate - Yahoo Finance
(CVKD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cadrenal Therapeutics secures $5.1 million in share sale - Investing.com
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin - TipRanks
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM - PR Newswire
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Drops By 7.2% - MarketBeat
Renaissance Technologies LLC Reduces Stock Position in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) - MarketBeat
Long Term Trading Analysis for (CVKD) - Stock Traders Daily
Jacksonville stocks rise as market hits record highs - Jacksonville Daily Record
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Rises By 22.8% - MarketBeat
Cadrenal Therapeutics Inc (CVKD-Q) QuotePress Release - The Globe and Mail
Where are the Opportunities in (CVKD) - Stock Traders Daily
Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy - TipRanks
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference - Kilgore News Herald
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Forecasted to Earn Q3 2024 Earnings of ($2.18) Per Share - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Trading Down 4.1% - Defense World
WATCH LIVE: Fed Chair Jerome Powell speaks after a 50bp interest rate cut - Investing.com
Cancer Biotech Nuvalent’s Stock Jumps on Positive Data - MSN
Cadrenal Therapeutics (CVKD) Stock Rallies In After-Market Trading Ahead Of Regulatory Meeting - Stocks Telegraph
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - MarketBeat
Eli Lilly invests $1.8B to boost manufacturing footprint in Ireland - MSN
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance
Cadrenal Therapeutics regains Nasdaq compliance - Investing.com India
Cadrenal gears up for FDA talks on heart drug trial - Investing.com India
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients - PR Newswire
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients - PR Newswire
Upcoming Stock Splits This Week (August 19 to August 23) – Stay InvestingTHE BHARAT EXPRESS NEWS - The Bharat Express News
Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested - MSN
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):